MedTrace Logo

Hostile Bias Modification Training (HBMT) Study

NCT04997356 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2023-12-21

No results posted yet for this study

Summary

The primary objective of the present protocol is to evaluate the effectiveness of real HBMT versus placebo on reducing HAB and aggression.

The secondary objectives of the present protocol are:

1. Investigate the role of individual difference variables on HAB, interpersonal aggression, and effects of HBMT.
2. Collect vocal recording data to inform the development of algorithms to predict emotional stress from changes in speech.

Conditions

  • Anger
  • Stress
  • Aggression

Interventions

BEHAVIORAL

Hostile Bias Modification Training

Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They will refrain from making words that can only form aggressive words.

BEHAVIORAL

Other training

Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words.

Sponsors & Collaborators

  • Walter Reed Army Institute of Research (WRAIR)

    lead FED

Principal Investigators

  • Margeaux V Auslander, PhD · Walter Reed Army Institute of Research (WRAIR)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-12
Primary Completion
2023-05-15
Completion
2023-05-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04997356 on ClinicalTrials.gov